RVMD
NASDAQ · Biotechnology
Revolution Medicines Inc
$193.06
-7.09 (-3.54%)
RVMD News4 articles
Revolution Medicines Rallies on RASONQUE Launch, Sales Forecasts
Revolution Medicines (RVMD) gains 2.3% premarket after RASONQUE's U.S. debut. RBC projects strong sales ramp, with Q3 at $28M and Q4 at $148M.
FDA Approves Rasonque, Revolution Medicines Stock Holds Steady
Revolution Medicines (RVMD) received FDA approval for Rasonque in pancreatic cancer, but shares rose only 0.8% as investors awaited launch details.
Tango Therapeutics Soars as Pancreatic Cancer Combo Shows 92% Response Rate
Tango Therapeutics shares rose sharply in premarket trading Monday after reporting a 92% objective response rate for its pancreatic cancer drug combo, with plans to move into Phase 3 testing.
Revolution Medicines Stock Gains Pre-Market on Promising Pancreatic Cancer Data
Revolution Medicines shares gained 1.9% premarket after Phase 3 data showed its experimental pill daraxonrasib nearly doubled median survival in pancreatic cancer to 13.2 months versus 6.7 months for chemotherapy.